ICB therapies, especially programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) monoclonal antibodies (anti-PD-1/PD-L1), could relieve the immune restriction and restore T lymphocyte function in the tumor microenvironment (TME) [7, 8]. Here, CD274 is linked to neoplasm.